Cargando…
Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction
INTRODUCTION: Our objective was to analyze the effect of spironolactone on cardiac remodeling after experimental myocardial infarction (MI), assessed by matricellular proteins levels, cardiac collagen amount and distribution, myocardial tissue metalloproteinase inhibitor-1(TIMP-1) concentration, myo...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786966/ https://www.ncbi.nlm.nih.gov/pubmed/24098808 http://dx.doi.org/10.1371/journal.pone.0076866 |
_version_ | 1782477808558145536 |
---|---|
author | Minicucci, Marcos F. dos Santos, Priscila P. Rafacho, Bruna P. M. Gonçalves, Andrea F. Silva, Renata A. C. Chiuso-Minicucci, Fernanda Azevedo, Paula S. Polegato, Bertha F. Okoshi, Katashi Pereira, Elenize J. Paiva, Sergio A. R. Zornoff, Leonardo A. M. |
author_facet | Minicucci, Marcos F. dos Santos, Priscila P. Rafacho, Bruna P. M. Gonçalves, Andrea F. Silva, Renata A. C. Chiuso-Minicucci, Fernanda Azevedo, Paula S. Polegato, Bertha F. Okoshi, Katashi Pereira, Elenize J. Paiva, Sergio A. R. Zornoff, Leonardo A. M. |
author_sort | Minicucci, Marcos F. |
collection | PubMed |
description | INTRODUCTION: Our objective was to analyze the effect of spironolactone on cardiac remodeling after experimental myocardial infarction (MI), assessed by matricellular proteins levels, cardiac collagen amount and distribution, myocardial tissue metalloproteinase inhibitor-1(TIMP-1) concentration, myocyte hypertrophy, left ventricular architecture, and in vitro and in vivo cardiac function. METHODS: Wistar rats were assigned to 4 groups: control group, in which animals were submitted to simulated surgery (SHAM group; n=9); group that received spironolactone and in which animals were submitted to simulated surgery (SHAM-S group, n=9); myocardial infarction group, in which animals were submitted to coronary artery ligation (MI group, n=15); and myocardial infarction group with spironolactone supplementation (MI-S group, n=15). The rats were observed for 3 months. RESULTS: The MI group had higher values of left cardiac chambers and mass index and lower relative wall thicknesses compared with the SHAM group. In addition, diastolic and systolic functions were worse in the MI groups. However, spironolactone did not influence any of these variables. The MI-S group had a lower myocardial hydroxyproline concentration and myocyte cross-sectional area compared with the MI group. Myocardial periostin and collagen type III were lower in the MI-S group compared with the MI-group. In addition, TIMP-1 concentration in myocardium was higher in the MI-S group compared with the MI group. CONCLUSIONS: The predominant consequence of spironolactone supplementation after MI is related to reductions in collagens, with discrete attenuation of other remodeling variables. Importantly, this effect may be modulated by periostin and TIMP-1 levels. |
format | Online Article Text |
id | pubmed-3786966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37869662013-10-04 Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction Minicucci, Marcos F. dos Santos, Priscila P. Rafacho, Bruna P. M. Gonçalves, Andrea F. Silva, Renata A. C. Chiuso-Minicucci, Fernanda Azevedo, Paula S. Polegato, Bertha F. Okoshi, Katashi Pereira, Elenize J. Paiva, Sergio A. R. Zornoff, Leonardo A. M. PLoS One Research Article INTRODUCTION: Our objective was to analyze the effect of spironolactone on cardiac remodeling after experimental myocardial infarction (MI), assessed by matricellular proteins levels, cardiac collagen amount and distribution, myocardial tissue metalloproteinase inhibitor-1(TIMP-1) concentration, myocyte hypertrophy, left ventricular architecture, and in vitro and in vivo cardiac function. METHODS: Wistar rats were assigned to 4 groups: control group, in which animals were submitted to simulated surgery (SHAM group; n=9); group that received spironolactone and in which animals were submitted to simulated surgery (SHAM-S group, n=9); myocardial infarction group, in which animals were submitted to coronary artery ligation (MI group, n=15); and myocardial infarction group with spironolactone supplementation (MI-S group, n=15). The rats were observed for 3 months. RESULTS: The MI group had higher values of left cardiac chambers and mass index and lower relative wall thicknesses compared with the SHAM group. In addition, diastolic and systolic functions were worse in the MI groups. However, spironolactone did not influence any of these variables. The MI-S group had a lower myocardial hydroxyproline concentration and myocyte cross-sectional area compared with the MI group. Myocardial periostin and collagen type III were lower in the MI-S group compared with the MI-group. In addition, TIMP-1 concentration in myocardium was higher in the MI-S group compared with the MI group. CONCLUSIONS: The predominant consequence of spironolactone supplementation after MI is related to reductions in collagens, with discrete attenuation of other remodeling variables. Importantly, this effect may be modulated by periostin and TIMP-1 levels. Public Library of Science 2013-09-30 /pmc/articles/PMC3786966/ /pubmed/24098808 http://dx.doi.org/10.1371/journal.pone.0076866 Text en © 2013 Minicucci et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Minicucci, Marcos F. dos Santos, Priscila P. Rafacho, Bruna P. M. Gonçalves, Andrea F. Silva, Renata A. C. Chiuso-Minicucci, Fernanda Azevedo, Paula S. Polegato, Bertha F. Okoshi, Katashi Pereira, Elenize J. Paiva, Sergio A. R. Zornoff, Leonardo A. M. Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction |
title | Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction |
title_full | Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction |
title_fullStr | Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction |
title_full_unstemmed | Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction |
title_short | Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction |
title_sort | mechanisms involved in the beneficial effects of spironolactone after myocardial infarction |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786966/ https://www.ncbi.nlm.nih.gov/pubmed/24098808 http://dx.doi.org/10.1371/journal.pone.0076866 |
work_keys_str_mv | AT minicuccimarcosf mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction AT dossantospriscilap mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction AT rafachobrunapm mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction AT goncalvesandreaf mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction AT silvarenataac mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction AT chiusominicuccifernanda mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction AT azevedopaulas mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction AT polegatoberthaf mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction AT okoshikatashi mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction AT pereiraelenizej mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction AT paivasergioar mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction AT zornoffleonardoam mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction |